Abstract 1401P
Background
The Kristen Rat Sarcoma (KRAS) activating mutation represents the most frequent oncogenic alteration in non-squamous non-small cell lung cancer (nsq-NSCLC). We aimed to describe the characteristics, treatment patterns and survival outcomes of a real-world population of advanced NSCLC according to the KRAS status.
Methods
From January 2011 to December 2021, we identified from the ESME database (NCT03848052) patients with a metastatic nsq-NSCLC. Patients with other druggable oncogenic alterations were excluded. Patients were grouped according to KRAS status: mutated (KRASm) versus wild-type (KRASwt). We analyzed KRASm subtype prevalence, patient and tumor characteristics, treatment history, and overall survival (OS). We analyzed patients’ survival outcomes according to the period of care to assess the impact of the implementation of immunotherapy as standard of care in France (available from 2017 in monotherapy and 2019 in combination with chemotherapy). Given that the proportional-hazards assumption is not verified, we used the restricted mean survival time (RMST). RMST is the average survival time until a milestone time point.
Results
We identified 6 818 patients of whom 2 916 (42.8%) were KRASm. Among the KRASm tumors, 1272 (43.6%) were KRAS-G12C. According to KRAS-status (mutant vs. wild-type): 41.4% vs. 33.8% were women (p<0.01); 3.9% vs. 10.9% were non-smokers (p<0.01); 45.0% vs. 37.0% had a high PD-L1 expression (>50%; p<0.01), 33.5% vs. 30.8% had brain metastasis (p=0.06). After a median follow-up of 52.9 months (95% CI 51.2 - 55.5), median OS was 13.2 months (95% CI 12.3 - 14.1) for KRASm and 15.1 months (95% CI 14.4 - 15.5) for KRASwt patients (p<0.01).
Table: 1401P
RSMT for OS at one year according to KRAS status and period of care
KRASwt | KRASm | |||||
n | RSMT 1year-OS | 95% CI | n | RSMT 1year-OS | 95% CI | |
2014-2016 | 1735 | 9.38 months | 9.22 – 9.52 | 1029 | 8.90 months | 8.68 – 9.09 |
2017-2018 | 1277 | 9.35 months | 9.17 – 9.53 | 1012 | 8.93 months | 8.71 – 9.13 |
2019-2021 | 767 | 9.33 months | 9.09 – 9.55 | 811 | 9.39 months | 9.15 – 9.58 |
Conclusions
KRASm appears to be a poor prognostic factor for metastatic nsq-NSCLC. The advent of chemotherapy-immunotherapy seems to have mitigated this pejorative impact. The prevalence of high PD-L1 in the KRASm tumors may explain this improvement of survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Unicancer.
Funding
This work was supported by Unicancer. Industrial partners (AstraZeneca, Roche, Janssen, MSD, BMS, Amgen) financially support the ESME Lung Cancer database but Unicancer manages the database (i.e. data collection, analysis and publication) independently.
Disclosure
Q. Thomas: Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Other: AstraZeneca. T. Filleron: Financial Interests, Personal, Other, working group: Janssen-Cilag; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Other, working group: Roche; Other, Consulting (compensated to my institution): Cellectis. J. Remon Masip: Financial Interests, Personal, Invited Speaker: Roche, Pfizer, Msd, Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Janssen, Takeda, Sanofi; Financial Interests, Personal, Expert Testimony: Ose Immunotherapeutics; Financial Interests, Institutional, Invited Speaker: Merck Portugal; Non-Financial Interests, Principal Investigator, PI of PECATI trial in Thymic malignancies endorsed by a grant by MSD: MSD; Non-Financial Interests, Other, Co-PI of APPLE trial (EORTC-1525): AstraZeneca; Non-Financial Interests, Member, Secretary of the Lung Cancer Group at the EORTC: EORTC. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape, Roche; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Other, DMSB: Roche. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Family member is an employee: AstraZeneca. D. Debieuvre: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Janssen, Pfizer, OSE Immunotherapeutics, Novartis, SanofiAventis, Amgen, Roche, Ipsen; Financial Interests, Personal, Invited Speaker: Gilead, Takeda, Pfizer; Financial Interests, Institutional, Funding: Roche, AstraZeneca, Janssen, MSD, Pfizer, BMS, Lilly, Boehringer Ingelheim, GSK, Chugaï, Chiesi, Novartis, Takeda, Bayer, SanofiAventis. C. Audigier Valette: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, AstraZeneca, Sanofi, Janssen; Financial Interests, Personal, Invited Speaker: Pfizer. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. S. Hiret: Financial Interests, Institutional, Advisory Board: BMS, Takeda, AstraZeneca, Sanofi, Roche; Financial Interests, Institutional, Other, support for attending meeting: Novartis. A.T. Stancu: Financial Interests, Institutional, Invited Speaker: Sanofi, AstraZeneca, Amgen, MSD, AstraZeneca, BMS; Financial Interests, Personal, Expert Testimony: BMS, Novartis; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Invited Speaker: IFCT. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. All other authors have declared no conflicts of interest.
Resources from the same session
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20